About Praxis Innere Medizin
Clinical Trials at Praxis Innere Medizin
During the past decade, Praxis Innere Medizin conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Praxis Innere Medizin
According to Clinical.Site data, the most researched conditions in "Praxis Innere Medizin" are
"Colorectal Cancer" (1 trials) and "Pancreatic Cancer" (1 trials). Many other conditions were trialed in "Praxis Innere Medizin" in a lesser frequency.
Clinical Trials Intervention Types at Praxis Innere Medizin
Most popular intervention types in "Praxis Innere Medizin" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "FOLFIRI regimen" (1 trials), "cisplatin" (1 trials), "docetaxel" (1 trials), "fluorouracil" (1 trials) and "gemcitabine hydrochloride" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Praxis Innere Medizin
The vast majority of trials in "Praxis Innere Medizin" are
2 trials for "All" genders.
Clinical Trials Status at Praxis Innere Medizin
Currently, there are NaN active trials in "Praxis Innere Medizin".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in Praxis Innere Medizin,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Praxis Innere Medizin, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 1 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".